Cronos Q4 Sales Jump 27% On Higher Cannabis Flower And Extract Sales, Reports Improved Profitability
On Thursday, Cronos Group Inc (NASDAQ:CRON) reported fourth-quarter sales of $30.3 million, up from $23.92 million, missing the consensus of $34.95 million.
The increase year-over-year was primarily driven by higher cannabis flower and extract sales in the Canadian market and higher cannabis flower sales in Israel and other countries.
Cronos GrowCo contributed $2.1 million of cannabis flower sales in Q4 2024.
The cannabinoid company reported earnings of 11 cents compared to a loss of 19 cents.
Also Next: Cronos CEO Mike Gorenstein Says He’s Optimistic About …